Our work thus reveals the therapeutic relevance of eEF1A2 as a target for pharmacological interventions in DMD and shows the feasibility of using repurposed drugs to activate this pathway for treating this neuromuscular disorder. This evidence concerns the gene EEF1A2 and Duchenne muscular dystrophy.